Last reviewed · How we verify
NCT05562999: HIPPO
Impact of Deep Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function
Phase 4 trial testing Rocuronium Bromide in Neuromuscular Blockade in 100 participants. Completed in 29 August 2024.
29 August 2024
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 18 November 2022 |
| Primary completion | 29 August 2024 |
| Estimated completion | 29 August 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Rocuronium Bromide (Rocuronium Bromide) — full drug profile →
- Rocuronium Bromide (Rocuronium Bromide) — full drug profile →
Conditions studied
- Neuromuscular Blockade — all drugs for Neuromuscular Blockade →
- Innate Inflammatory Response — all drugs for Innate Inflammatory Response →
- Quality of Life — all drugs for Quality of Life →
- Postoperative Complications — all drugs for Postoperative Complications →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Neuromuscular Blockade or Innate Inflammatory Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Monocenter randomized controlled trial to compare the effect of deep neuromuscular blockade (NMB) versus moderate NMB during total hip replacement surgery on postoperative quality of recovery and innate immune function.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Deep versus moderate neuromuscular blockade during total hip arthroplasty to improve postoperative quality of recovery and immune function: protocol for a randomised controlled study.
Bijkerk V, Visser J, Jacobs LMC, Keijzer C, et al · · 2023 · cited 4× · PMID 37640469 · DOI 10.1136/bmjopen-2023-073537 -
The effect of general versus spinal anesthesia on perioperative innate immune function in patients undergoing total hip arthroplasty.
Jacobs LMC, Bijkerk V, van Eijk LT, Joosten LAB, et al · · 2025 · cited 1× · PMID 39773137 · DOI 10.1186/s12871-024-02883-1 -
Deep versus Moderate Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function: A Randomized Controlled Trial.
Bijkerk V, Jacobs LMC, Rijnen WHC, Keijzer C, et al · · 2026 · PMID 40674253 · DOI 10.1213/ane.0000000000007639
Verify or expand the search:
- PubMed search for NCT05562999
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rocuronium Bromide
Trials testing the same drug.
- NCT06399445 — Measurement of Blood Loss in Adenotonsillectomy During General Anesthesia According to the Application of Nondepolarizin · Phase 4 · recruiting
- NCT05872451 — Current Intensity for the Obturator Nerve Block · NA · completed
- NCT05687253 — Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery · Phase 2 · completed
- NCT05619848 — Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery · EARLY_PHASE1 · completed
- NCT05097508 — Effect of Atracurium and Rocuronium on the State and Response Entropy During Isoflurane Anesthesia · EARLY_PHASE1 · completed
Other recruiting trials for Neuromuscular Blockade
Currently open trials in the same condition.
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
- NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05562999 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05562999.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing